Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.
The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions.
Mbori-Ngacha
Dorothy
D
Department of Pediatrics, University of Nairobi, Nairobi, Kenya.
Richardson
Barbra A
BA
Overbaugh
Julie
J
Panteleeff
Dana DeVange
DD
Nduati
Ruth
R
Steele
Matt
M
John-Stewart
Grace
G
D002584:Cervix Uteri / Q000821:virology*; D005260:Female; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology; D006207:Half-Life; D006801:Humans; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D014621:Vagina / Q000821:virology*; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology* / Q000627:therapeutic use
D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine